about
Clopidogrel's role in the management of atherosclerotic disease: a focus on acute coronary syndromesPharmacokinetics and pharmacodynamics of terbogrel, a combined thromboxane A2 receptor and synthase inhibitor, in healthy subjectsClinical use of new antithrombotic therapies for medical management of acute coronary syndromesOrbofiban: an orally active GPIIb/IIIa platelet receptor antagonistThe inhibition of oxygen radical release from human neutrophils by resting platelets is reversed by administration of acetylsalicylic acid or clopidogrelRationale for the use of platelet aggregation inhibitors in PAD patientsAntiplatelet therapy in the prevention of ischemic vascular events: literature review and evidence-based guidelines for drug selection.Efficacy and safety of abciximab in diabetic patients who underwent percutaneous coronary intervention with thienopyridines loading: a meta-analysis.Platelet adhesion receptors: novel targets for anti-thrombotic therapy.Aggrenox: a fixed-dose combination of aspirin and dipyridamole.Effects of kiwi fruit consumption on platelet aggregation and plasma lipids in healthy human volunteers.Glicoprotein (GP) IIb/IIIa inhibitors for acute stroke treatment.Mechanism of endothelial cyto-protective and thrombo-resistance effects of sildenafil, vardenafil and tadalafil in male rabbit.Noncholesterol-lowering effects of statins.The role of 3-hydroxy-3-methylglutaryl coenzyme a reductase inhibitors (statins) in modern rheumatologyThrombosis recanalization by paeoniflorin through the upregulation of urokinase‑type plasminogen activator via the MAPK signaling pathway.New horizons in platelet research: understanding and harnessing platelet functional diversity.Antithrombotic activity of a newly synthesized coumarin derivative 3-(5-hydroxy-2,2-dimethyl-chroman-6-yl)-N-{2-[3-(5-hydroxy-2,2-dimethyl-chroman-6-yl)-propionylamino]-ethyl}-propionamide.Synthesis and biological evaluation of some dibenzofuran-piperazine derivatives.Bioequivalence and tolerability study of two brands of clopidogrel tablets, using inhibition of platelet aggregation and pharmacodynamic measures.A peripherally restricted P2Y12 receptor antagonist altered rat tumor incidences with no human relevance: Mode of action consistent with dopamine agonism.The in vivo pharmacological profile of CS-747, a novel antiplatelet agent with platelet ADP receptor antagonist properties.A comparative study of antioxidative activity of calcium-D-glucarate, sodium-D-gluconate and D-glucono-1,4-lactone in a human blood platelet model.Does the use of statins compromise the effectiveness of platelet inhibition by clopidogrel?
P2860
Q28167896-C8AACDAA-7A45-4010-870F-375F034D7415Q28169037-5A5A1795-3C98-4C68-B0DC-EF589AF0405AQ28177271-2D3F771B-24DD-4F1B-B78F-26DBDB85A5B6Q28181764-6EE8B38C-A144-42E5-9AF2-33FC4EE9540EQ28184338-BD020B68-054E-4447-8D2A-EA31DBDE671EQ28192093-C8EB37E0-9FDD-4E5E-96FC-E4866ED302E2Q33732646-68E52681-3D35-48F4-8C85-838F980F88F7Q33934090-7BEB59EB-1C32-4D4D-885F-EBA1D8F53287Q33951293-0A65CF5C-90CE-4C93-8649-A48ECDA06C51Q34093604-42EAA784-928A-484F-97BE-C0B79C6F6346Q34348622-8A63A739-5914-4182-AC82-FDF9B4BFC727Q35008537-CB28ADA2-96A7-4D3E-AEF5-79CE802E0BA9Q35232187-D008AFA4-E275-4DAF-863B-F82556FC5140Q35551180-77D95AF7-33CD-4D34-BE8F-FDF26A7C406AQ36059492-D04AACE0-729B-489D-A127-7FB700F5B0D0Q36931196-B1BCF917-CB8D-4EBF-AE49-B0ECAAD5DA37Q38419319-6411E413-C4C4-4BE5-92D0-B94B39F30C5EQ39444308-BDC1353D-15A1-49CE-A71A-D113329632F4Q40307089-8E7D9482-152D-45BD-ADCF-4D6D7CF1FF1DQ40563626-E125B776-4D44-4AA4-918A-50C9B3A34D1BQ41680809-90F5D2F9-4369-46BF-9FDD-BB032C63F92EQ41906079-E2A4F9E8-3D05-4D06-89DC-7ED3806DC412Q42875481-C6248ED9-960D-4E56-B23D-F549D6C4CF7BQ44941568-9E45E014-D2BE-4232-B360-8B86F07FFDCD
P2860
description
1995 nî lūn-bûn
@nan
1995年の論文
@ja
1995年学术文章
@wuu
1995年学术文章
@zh-cn
1995年学术文章
@zh-hans
1995年学术文章
@zh-my
1995年学术文章
@zh-sg
1995年學術文章
@yue
1995年學術文章
@zh
1995年學術文章
@zh-hant
name
Antiplatelet drugs. A comparative review.
@en
type
label
Antiplatelet drugs. A comparative review.
@en
prefLabel
Antiplatelet drugs. A comparative review.
@en
P1433
P1476
Antiplatelet drugs. A comparative review.
@en
P2093
P356
10.2165/00003495-199550010-00002
P577
1995-07-01T00:00:00Z
P6179
1048825104